Todas as matérias desta seção, das mais recentes às mais antigas — página 132 de 371.
Invivyd (NASDAQ:IVVD) announced it received formal notification from the FDA that the Emergency Use Authorization for its monoclonal antibody treatment PEMGARDA will terminate on June 29, 2027.
Innovative Eyewear (NASDAQ:LUCY) reported preliminary unaudited net sales of approximately $0.99 million for Q2 2026, representing a year-over-year increase of about 71%.
Ondas Holdings (NASDAQ:ONDS) said it has entered into an agreement to acquire DZYNE Technologies in a transaction valued at approximately $875.8 million in cash and stock.
Iridium (NASDAQ:IRDM) announced it completed the acquisition of Aireon to combine global satellite communications with space-based air traffic surveillance.
easyJet said it has agreed in principle to a £5.5 billion ($7.3 billion) cash offer from U.S. investment firm Castlelake after rejecting four earlier proposals.
Agenus (NASDAQ:AGEN) reported updated Phase 1b clinical data for its botensilimab (BOT) and balstilimab (BAL) combination in patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases.
Solaris Energy Infrastructure (NYSE:SEI) announced it executed an agreement to acquire Global Energy Services Alliance to scale up its full-cycle power generation solutions.
Ceva (NASDAQ:CEVA) announced a landmark licensing agreement with a major U.S. software and AI platform company to support a custom AI silicon program aimed at next-generation intelligent computing devices.
Ionis Pharmaceuticals (NASDAQ:IONS) announced it completed patient enrollment in the pivotal pediatric cohort of its global Phase 3 REVEAL clinical study evaluating its investigational RNA-targeted medicine, obudanersen.
Pharvaris (NASDAQ:PHVS) announced the FDA accepted its regulatory application for its 20 mg hereditary angioedema on-demand treatment capsule.
Maximus (NYSE:MMS) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.33 per share to reward equity investors.
Lindsay (NYSE:LNN) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.38 per share.
AtaiBeckley (NASDAQ:ATAI) announced it completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating VLS-01 for treatment-resistant depression.
AEVEX (NYSE:AVEX) announced it secured a $17.5 million follow-on defense contract under its Global Solutions business segment to continue delivering critical intelligence services.
Natera (NASDAQ:NTRA) announced publication of new clinical data in JAMA Oncology evaluating its Signatera molecular residual disease (MRD) test in patients with resected colorectal liver metastases (CRLM).
High Tide (NASDAQ:HITI) said it has approved a Temporary Shareholder Rights Plan alongside an Amended and Restated Shareholder Rights Plan, both dated June 26, 2026.
Clarivate (NYSE:CLVT) said it has agreed to sell its Life Sciences & Healthcare (LS&H) segment to Altaris for a total consideration of $600 million.
Solstice Advanced Materials (NASDAQ:SOLS), the Honeywell (NASDAQ:HON) spinoff, is in talks to merge with Element Solutions (NYSE:ESI) in a deal that could value the combined company at about $27 billion, including debt.
Oil prices fell on Monday after OPEC+ agreed to increase production targets starting in August, adding pressure to a market already focused on improving global supply conditions.
Kosmos Energy (NYSE:KOS) reported strong operational progress in the first half of 2026, driven by higher production from its Jubilee field in Ghana and steady LNG performance in Mauritania and Senegal.
Molecular Partners (NASDAQ:MOLN) said its Phase 1/2a U.S. study of MP0712 is actively dosing patients in a trial targeting DLL3-positive small cell lung cancer and neuroendocrine tumors.
United Microelectronics Corporation (NYSE:UMC) reported unaudited June 2026 net sales of NT$23.12 billion, reflecting a 22.85% increase compared with NT$18.82 billion in June 2025.
